Ariella,
This indeed is wonderful news for PARS. The reasoning is quite simple. In CNN's version of the news report submitted by David, it reads,
"However, tamoxifen also has been associated with increased risks for cancer in the uterine lining and for blood clots in the lungs. Those risks prompted The National Women's Health Network in Washington to criticize the study."
In the data submitted by our scientific team on the PARS webpage, it reports that "tamoxifen methiodide (the PARS analog)has a uniquely designed safety profile. First, tamoxifen methidide is significantly less estrogenic than tamoxifen in the uterus, suggesting a lower incidence of uterine cancer."
Although it is very early to make lofty predictions, it is quite evident that this study is great news for PARS. Not only is tamoxifen proven to be efficacious in the prevention of breast cancer, in early studies, the PARS analog reduces the uterine cancer side effect. It stands to reason that if PARS can bring this compound through the FDA approval process, it may not be just another "me too" drug, but may become the Rx of choice due to its safety profile. This mix of efficacy and safety may not only enable tamoxifen methiodide capture market share, but also expand the market, as doctor's should be more comfortable prescribing it.
Again, PARS has a long way to go on this one, but the news sounds very positive.
Best Regards,
Todd
|
